{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:59:37Z","timestamp":1794491977284,"version":"4.9.1"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi240615-4\"><jats:title>Importance<\/jats:title><jats:p>Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked to inadequate screening and treatment can inform implementation strategies to facilitate guideline-recommended CKD care.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240615-5\"><jats:title>Objective<\/jats:title><jats:p>To identify risk factors for nonconcordance with guideline-recommended CKD screening and treatment in patients with T2D.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240615-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study was performed at 20 health care systems contributing data to the US National Patient-Centered Clinical Research Network. To evaluate concordance with CKD screening guidelines, adults with an outpatient clinician visit linked to T2D diagnosis between January 1, 2015, and December 31, 2020, and without known CKD were included. A separate analysis reviewed prescription of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in adults with CKD (estimated glomerular filtration rate [eGFR] of 30-90 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> and urinary albumin-to-creatinine ratio [UACR] of 200-5000 mg\/g) and an outpatient clinician visit for T2D between October 1, 2019, and December 31, 2020. Data were analyzed from July 8, 2022, through June 22, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240615-7\"><jats:title>Exposures<\/jats:title><jats:p>Demographics, lifestyle factors, comorbidities, medications, and laboratory results.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240615-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Screening required measurement of creatinine levels and UACR within 15 months of the index visit. Treatment reflected prescription of ACEIs or ARBs and SGLT2 inhibitors within 12 months before or 6 months following the index visit.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240615-9\"><jats:title>Results<\/jats:title><jats:p>Concordance with CKD screening guidelines was assessed in 316\u202f234 adults (median age, 59 [IQR, 50-67] years), of whom 51.5% were women; 21.7%, Black; 10.3%, Hispanic; and 67.6%, White. Only 24.9% received creatinine and UACR screening, 56.5% received 1 screening measurement, and 18.6% received neither. Hispanic ethnicity was associated with lack of screening (relative risk [RR], 1.16 [95% CI, 1.14-1.18]). In contrast, heart failure, peripheral arterial disease, and hypertension were associated with a lower risk of nonconcordance. In 4215 patients with CKD and albuminuria, 3288 (78.0%) received an ACEI or ARB; 194 (4.6%), an SGLT2 inhibitor; and 885 (21.0%), neither therapy. Peripheral arterial disease and lower eGFR were associated with lack of CKD treatment, while diuretic or statin prescription and hypertension were associated with treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi240615-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study of patients with T2D, fewer than one-quarter received recommended CKD screening. In patients with CKD and albuminuria, 21.0% did not receive an SGLT2 inhibitor or an ACEI or an ARB, despite compelling indications. Patient-level factors may inform implementation strategies to improve CKD screening and treatment in people with T2D.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.18808","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T15:38:06Z","timestamp":1719416286000},"page":"e2418808","source":"Crossref","is-referenced-by-count":39,"title":["Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes"],"prefix":"10.1001","volume":"7","author":[{"given":"Daniel","family":"Edmonston","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lydon","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Mulder","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Lampron","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Marsolo","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Goss","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Division of Nephrology; Department of Medicine, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj C.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Family and Preventive Medicine, Rush University Medical Center, Chicago, Illinois"},{"name":"Rush Alzheimer\u2019s Disease Center, Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Schuyler","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Cardiology; Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Fonesca","sequence":"additional","affiliation":[{"name":"Division of Endocrinology; Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Machineni","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fort","sequence":"additional","affiliation":[{"name":"Ochsner Health, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Pitlosh","sequence":"additional","affiliation":[{"name":"Department of Family & Preventive Medicine, Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaykumar","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz S.","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Division of Cardiology; Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Academic Internal Medicine and Geriatrics; Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M.","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine at Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Health Services and Behavioral Research; Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden B.","family":"Bosworth","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"},{"name":"Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Medical Center, Durham, North Carolina"},{"name":"Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke University School of Nursing, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha J.","family":"Pagidipati","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"1","key":"zoi240615r2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns\u2014NHANES 2007-2012.","volume":"4","author":"Wu","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"zoi240615r3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.672350","article-title":"Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019.","volume":"12","author":"Deng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"zoi240615r4","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.2337\/dc20-S016","article-title":"16. Diabetes advocacy: Standards of Medical Care in Diabetes\u20142019.","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"issue":"4S","key":"zoi240615r5","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","journal-title":"Kidney Int"},{"issue":"20","key":"zoi240615r7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi240615r8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi240615r9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi240615r10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi240615r11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER.","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"zoi240615r12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi240615r13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi240615r14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240615r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.10704","article-title":"Quality of chronic kidney disease management in Canadian primary care.","volume":"2","author":"Bello","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi240615r16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2215\/CJN.00060119","article-title":"Trends in quality of care for patients with CKD in the United States.","volume":"14","author":"Tummalapalli","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"zoi240615r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.27014","article-title":"Trends in chronic kidney disease care in the US by race and ethnicity, 2012-2019.","volume":"4","author":"Chu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi240615r18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration system.","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"zoi240615r19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.34067\/KID.0007862021","article-title":"Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis.","volume":"3","author":"Zhuo","year":"2022","journal-title":"Kidney360"},{"issue":"12","key":"zoi240615r20","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease.","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi240615r21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/amiajnl-2014-002747","article-title":"Launching PCORnet, a national patient-centered clinical research network.","volume":"21","author":"Fleurence","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"zoi240615r22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5334\/egems.199","article-title":"Evaluating foundational data quality in the National Patient-Centered Clinical Research Network (PCORnet\u00ae).","volume":"6","author":"Qualls","year":"2018","journal-title":"EGEMS (Wash DC)"},{"issue":"19","key":"zoi240615r23","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi240615r24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12874-018-0519-5","article-title":"Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification.","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"zoi240615r25","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi240615r26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.mayocp.2020.07.037","article-title":"Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database.","volume":"96","author":"Folkerts","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"zoi240615r27","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 US health care organizations.","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi240615r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease.","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi240615r29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment.","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"zoi240615r30","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1681\/ASN.2006050493","article-title":"African ancestry, socioeconomic status, and kidney function in elderly African Americans: a genetic admixture analysis.","volume":"17","author":"Peralta","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"zoi240615r31","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease.","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"zoi240615r32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient.","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"issue":"25","key":"zoi240615r33","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"zoi240615r34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.ajkd.2017.09.017","article-title":"Population health for CKD and diabetes: lessons from the Indian Health Service.","volume":"71","author":"Narva","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"zoi240615r35","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2311708","article-title":"Pragmatic trial of hospitalization rate in chronic kidney disease.","volume":"390","author":"Vazquez","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi240615r36","first-page":"1","article-title":"A quality improvement initiative targeting chronic kidney disease metrics through increased urinary albumin testing.","volume":"25","author":"Park","year":"2020","journal-title":"Perm J"},{"issue":"15","key":"zoi240615r37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial.","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"issue":"22","key":"zoi240615r38","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","article-title":"Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial.","volume":"79","author":"Ghazi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"zoi240615r39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jacc.2023.02.005","article-title":"Cluster-randomized trial comparing ambulatory decision support tools to improve heart failure care.","volume":"81","author":"Mukhopadhyay","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"zoi240615r6","volume-title":"2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"United States Renal Data System","year":"2022"},{"key":"zoi240615r1","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report. Reviewed November 29, 2023. Accessed April 6, 2023. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2820367\/edmonston_2024_oi_240615_1718381646.27775.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T15:38:14Z","timestamp":1719416294000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.18808","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}